|
News For ABBV;ABT From The Last 14 Days Check below for free stories on ABBV;ABT the last two weeks. |
|
|
| May 24, 2013 |
| 08:22 EDT |  | ABBV | Leerink's biotech analysts hold an analyst/industry conference call
 Subscribe for More Information |
|
| May 22, 2013 |
| 07:28 EDT | | ABT | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link |
|
| May 21, 2013 |
| 08:03 EDT |  | ABT | Abbott announces CE Mark for coronary drug eluting stent
Subscribe for More Information |
|
| May 20, 2013 |
| 10:51 EDT | | ABBV | AbbVie initiates Phase 3 clinical study for atrasentan
Subscribe for More Information |
|
| 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 07:42 EDT | | ABBV | Cohasset Associates to host a conference
National Conference on Managing Electronic Records is being held in Chicago on May 20-22. |
|
| 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. |
|
| May 17, 2013 |
| 05:15 EDT | | ABBV | Galapagos, AbbVie extend GLPG0634 collaboration
Galapagos and AbbVie announced an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the study, expected in Q2 of 2015, AbbVie will pay Galapagos $50M. The terms of the collaboration extension are in addition to previously agreed upon financial terms. AbbVie will be responsible for funding and performing clinical development beyond Phase 2, and completing regulatory and commercialization activities. Galapagos will start an 20-week, Phase 2A/B study with GLPG0634 in 180 patients suffering from Crohn's disease by early 2014. |
|
| May 16, 2013 |
| 08:55 EDT | | ABBV | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 15, 2013 |
| 17:26 EDT | | ABBV | Third Point gives quarterly update on stakes
NEW STAKES: Virgin Media (VMED), Tiffany (TIF), B/E Aerospace (BEAV), Anadarko (APC), and Thermo Fisher (TMO). INCREASED STAKES: International Paper (IP), Abbvie (ABBV), TransDigm (TDG), Constellation Brands (STZ), and Dollar General (DG). DECREASED STAKES: Delphi (DLPH), Murphy Oil (MUR), AIG (AIG), LyondellBasell (LYB), and Liberty Global (LBTYA). LIQUIDATED STAKES: Tesoro (TSO), Morgan Stanley (MS), Symantec (SYMC), Herbalife (HLF), and Illumina (ILMN). |
| |
| 10:13 EDT |  | ABBV | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 07:59 EDT | | ABBV | AbbVie initiated with an Outperform at Cowen
Subscribe for More Information |
|
| May 14, 2013 |
| 10:20 EDT |  | ABBV | AbbVie volatility at 22 into ASCO
Subscribe for More Information |
|
| 09:27 EDT | | ABBV | AbbVie and Alvine Pharmaceutical enter into collaboration
Subscribe for More Information |
|
| 07:24 EDT | | ABBV | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
|
|
|
|
